Assessing new health technologies: Lessons to be learned from drugs

Medical Journal of Australia

Volumn 171, Issue 10, 1999, Pages 554-556

  Henry, David A ^a   Hill, Suzanne R ^b  

^a NEWCASTLE MATER HOSPITAL   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOMEDICAL TECHNOLOGY ASSESSMENT; COST EFFECTIVENESS ANALYSIS; DRUG MANUFACTURE; DRUG USE; EVIDENCE BASED MEDICINE; PURCHASING; REVIEW;

EID: 0033571134     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.1999.tb123795.x     Document Type: Review

References (18)

1. Fineberg HV, Hiatt HH. Evaluation of medical practices. The case for technology assessment. New Engl J Med 1979; 301: 1086-1091.
2. Drummond MF. Basing prescription drug payment on economic analysis: The case of Australia. Health Aff (Millwood) 1992 Winter; 11: 191-196.
3. Freund DA, Evans D, Henry D, Dittus R. Implications of the Australian guidelines for the United States. Health Aff (Millwood) 1992 Winter; 11: 202-206.
4. Johannesson M. The Australian guidelines for subsidisation of pharmaceuticals. The road to cost-effective drug prescribing? PharmacoEconomics 1992; 2: 355-362.
5. Salkeld G, Mitchell A, Hill S. Pharmaceuticals. In: Mooney G, Scotton R, editors. Economics and Australian health policy. Sydney: Allen and Unwin, 1999: 115-136.
6. Freemantle N. Does the UK National Health Service need a fourth hurdle for pharmaceutical reimbursement to encourage the more efficient prescribing of pharmaceuticals? Health Policy 1999; 46: 255-265.
7. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomised controlled trials. J Clin Epidemiol 1997; 50: 683-691.
8. Hill S, Henry D, Pekarsky B, Mitchell A. Economic evaluation of pharmaceuticals: what are reasonable standards for clinical evidence - the Australian experience. Br J Clin Pharmacol 1997; 44; 421-425.
9. Research and effective health care [editorial]. Lancet 1993; 342: 64.
10. Henry D, Lim L, Garcia Rodriguez LA, et al. Variability and risk of major upper gastrointestinal complications with individual NSAIDs: results of a collaborative meta-analysis. BMJ 1996; 312: 1563-1566.
11. McManus P, Primrose J, Henry D et al. Pattern of use of non-steroidal anti-inflammatory drugs in Australia 1990-1994. Med J Aust 1996; 164: 589-592.
12. Ware JH, Antman EM. Equivalence trials. New Engl J Med 1997; 337: 1159-1161.
13. Hale AS. ABC of mental health: Depression. BMJ 1997; 315: 43-46.
14. Freemantle N, House A, Song F, et al. Prescribing selective serotonin reuptake inhibitors as strategy for prevention of suicide. BMJ 1994; 309: 249-253.
15. Roberts TE, and the Extracorporeal membrane Oxygenation Economics Working Group on behalf of the Extra corporeal membrane Oxygenation Trial Steering Group. Economic evaluation and randomised controlled trial of extracorporeal membrane oxygenation: UK collaborative trial. BMJ 1998; 317: 911-916.
16. Kerridge I, Lowe M, Henry D. Ethics and evidence-based medicine. BMJ 1998; 316: 1151-1153.
17. Chalmers I. What do I want from health researchers and researches when I am a patient? BMJ 1995; 310: 1315-1318.
18. Williams B. Morality. Cambridge: Cambridge University Press, 1972.